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Abstract
Disorders related to the misuse of certain drugs represent not only a worldwide public 
health problem, but also an economic and social issue. Adolescents and children represent 
the most vulnerable population for drug consumption and addiction. At this early stage 
in life, a crucial phase of the neurodevelopmental process, substance abuse can induce 
brain plasticity mechanisms that may produce long-lasting changes in neural circuitry 
and ultimately behavior. One of the consequences of these changes is the impairment of 
cognitive functions, with academic negative impact in the acquisition of new knowledge. 
In this chapter, we will describe the effects of illicit substances of abuse, both stimulants 
and depressants as well as prescription drug misuse and its influence of on learning and 
memory processes. Recent evidence on the new so-called smart drugs is also discussed.
Keywords: abuse, cognition, performance, nootropic, smart, stimulants, depressant, 
memory, impairment, adolescent
1. Introduction
According to United Nations Office on drugs and Crime, in 2015, around a quarter of a bil-
lion people used drugs, and approximately 29.5 million showed drug use disorders, including 
dependence [1]. Drug abuse produces health disruption. Disorders related to the use of certain 
drugs are associated with an important worldwide rate of morbidity. A wide range of drug-
induced neurobiological modifications have been described; some of which can affect learning 
and memory functions. Stimulant drugs, like nicotine and amphetamine, improve cognitive 
function at lower doses but impair memory performance at higher doses. Depressant drugs, like 
alcohol, can cause long-term effects on prefrontal cortex function, disrupting cognitive abilities.
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Several studies have suggested that the influence of psychoactive drugs on learning and 
memory might be explained, at least in part, because of the shared neurobiological mecha-
nisms involved in learning and memory processes and the drug-induced structural and func-
tional changes in the brain. Anatomically, there is an important overlap between the neural 
substrates of learning and memory and those of addiction. Some of the areas that show over-
lap include the cerebral cortex, hippocampus, amygdala and striatum [2]; all of them are 
components of the mesolimbic dopaminergic system.
Adolescence is a sensitive period in brain development characterized by a decrease in gray 
matter and an increase in white matter. The diminution of gray matter is thought to be due, 
at least in part, to the process of synaptic pruning, which is the developmental refinement 
of brain circuits by removal of superfluous synapses [3]. Early drug exposure is associated 
with frontal lobe damage, low cognitive performance and emotional learning, as well as other 
behaviors. Moreover, it has been demonstrated that adolescent exposure to both prescription 
and social drugs impairs cognition, as well as other behaviors, in the adulthood [4].
There is a clear bidirectional relationship between abuse of drugs and poor academic achieve-
ment. It has been suggested that cognitive deficits could make adolescents more vulnerable 
to substance abuse than others; conversely, other proposals argue that substance abuse is the 
source of cognitive impairments [5–7]. Of course the two possibilities are not mutually exclu-
sive; teenagers with poor academic performance may be more prone to abusing illicit drugs, 
which may impair their results at school even further. While the several social science theories 
have been proposed to try to explain each of these phenomena [6], in the following text, we 
will focus on the cognitive consequences of adolescent substance abuse on the functioning 
of the nervous system that may have a deleterious impact on cognitive abilities, academic 
achievement and long-term satisfaction with life in general.
2. Stimulant drugs
Memory is the natural counterpart of learning; both are necessary for behavioral change that 
precedes survival of species. Substance abuse has been demonstrated to exert detrimental 
impact upon learning and memory. According to the United Nations Office on Drugs and 
Crime through World Drug Report 2017, 29.5 million people globally suffer from drug use 
disorders [8]. Cognitive impairment is a well-established consequence of long-term substance 
abuse, with stimulants as nicotine, methamphetamine (MA) and cocaine leading deficits in 
the area of executive function. Stimulants are a class of illicit drugs that can have negative 
impact on individuals who use them, although this impact might be masked by the believed 
benefits (Table 1) [9].
2.1. Nicotine
Nicotine is the main psychoactive component of tobacco and the responsible agent of tobacco 
dependency. According to the World Health Organization, despite its severe health conse-
quences, about one billion people smoke worldwide.
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When nicotine is administered acutely, it produces positive effects improving cognitive func-
tions, including sustained attention, vigilance, visuospatial selective attention, spatial working 
memory and associative memory, both in animal models [10] and in humans [11]. Conversely, 
a vast amount of literature has showed that chronic nicotine use leads to tolerance, and 1 h 
after cessation of nicotine exposure, nicotine withdrawal syndrome emerges and it is charac-
terized by mild cognitive deficits. In other words, nicotine tends to improve cognitive func-
tion at lower doses and impair performance at higher doses [12]. Furthermore, heavy smokers 
under acute abstinence from smoking experience decreased neurocognitive functions, includ-
ing impairments in sustained attention, working memory and response inhibition [13]. Strong 
activation of memory-related brain regions that include the dorsolateral prefrontal cortex and 
hippocampus has been correlated with smoking-related cues in adult heavy smokers [14]. 
These areas are involved in emotional learning and reward-related learning.
Some reports have shown that nicotine and nicotinic agonists, as mecamylamine, evoked cog-
nitive enhancement by potentiating the release of dopamine [12, 15]. Working memory is criti-
cally reliant on dopaminergic neurotransmission. In addition, rodent studies have revealed a 
direct relationship between dopamine release in the prefrontal cortex and on memory task 
accuracy [16]. Moreover, cholinergic systems and nicotinic receptors are essential for cognitive 
processes and have been implicated in diseases associated with cognitive impairment [17].
Drug Cognitive 
process
Effect Model Reference
Stimulant drugs Attention
Vigilance
Memory
Acute:
Improving selective visuospatial attention, 
spatial working memory and associative 
memory
Monkey
Rat
Mice
Zebrafish
Human
[10, 11]
Chronic:
Tolerance
Withdrawal syndrome
Mild deficits in memory and inhibition 
response
Disruption in prospective and visual memory, 
verbal ability, reasoning and decision making
Human
Rat
[13, 25–27, 29]
Depressant drugs Attention
Memory
Acute/low doses:
Facilitation in working memory, verbal fluency 
and executive functions
Impaired working memory, verbal fluency and 
executive functions
Human [37, 38, 41, 
55–57]
Chronic/high doses:
Disruption in working and episodic memory, 
consolidation memory, attention and memory 
Also, presence of blackouts
Human [39, 61–67]
Table 1. Effects of the stimulants and depressant drugs in cognitive functions.
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2.2. Methamphetamine (MA)
MA abuse represents a serious public health issue associated with a high likelihood of relapse. 
By 2008, nearly 25 million people worldwide were estimated to have used MA, with abuse 
being among younger age groups [18]. MA used is mainly for recreational purposes and 
it is known to induce a variety of desirable effects, including increased energy levels, posi-
tive mood, euphoria, reduced appetite, weight loss, enhanced mental acuity and social and 
sexual disinhibition [19]. In addition, MA-dependent individuals often claimed enhancement 
of cognitive function and ability to focus following drug administration. However, this drug 
induces long-term changes in the brain structure and function, changes in synaptic plastic-
ity, cell death via apoptosis and neurotoxicity, and consequently, it causes dependence and 
withdrawal syndrome [20].
Anatomically, MA has a preferential neurotoxic effect on the frontostriatal systems that con-
tributes to both emotion dysregulation and neurocognitive impairment [21]. For instance, 
MA addicts showed impaired performance on tests of cognitive flexibility, which measures 
the ability to modify behavior when presented with new information or changing outcomes. 
These deficits may impair MA addicts from altering their habitual drug abuse behavior, lead-
ing to an inability to initiate abstinence or resist relapse [22]. Cellular mechanism of this MA 
impairment has been associated with long-term downregulation of dopamine transporters, 
suggesting that there are structural changes in some of the dopamine nerve terminals [23]. 
Other findings suggest that MA use causes changes in the metabolism of the insula and stria-
tum [24]. In a study in humans, MA-dependent participants had significantly lower results 
than control participants on memory tasks, including prospective memory and visual mem-
ory [25]. Accordingly, studies in young adult MA abusers have shown impaired verbal ability, 
deficits in psychomotor processing [26], reasoning deficits reflecting problematic decision-
making abilities as well as retrospective memory task impairment [27].
The evidences pointed that acute administration of MA improves cognitive functions, while 
chronic consumption of MA deteriorates them.
2.3. Cocaine
Cocaine has long been one of the most common recreational stimulants, especially for adoles-
cents. A recent estimate indicates that half a million of United States habitants use this drug 
weekly; in this sense, cocaine addiction represents a substantial burden for societies worldwide, 
linked to adverse outcomes such as violence, suicide and disability, as well as high rates of chronic 
relapse [28]. In the brain, crack cocaine use has been shown to cause toxic effects, particularly in 
the prefrontal cortex. These abnormalities are associated with neuropsychological impairments.
Abundant evidence has shown that cocaine withdrawal induces memory decline after its 
chronic use. It has been reported that chronic cocaine users showed significant harm on ver-
bal memory and fluency as well as deficits in cognitive flexibility, but not in spatial memory, 
after acute withdrawal. Further, Briand and colleagues observed that object recognition was 
disturbed after withdrawal from chronic exposure to cocaine by an object recognition task in 
2-week abstinent rats [29]. Several reports have shown that the insular and prefrontal corti-
ces, involved in cognitive control, show reduced activity on selective attention and inhibitory 
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 control tasks in cocaine addicts [30]. These brain areas may be involved in the maintenance and 
relapse of drug use [31]. Individuals with cocaine abuse and dependence show higher insula, 
frontal and/or striatum activation in response to cocaine-related cues, reflecting heightened 
attention in response to this drug [32, 33]. Furthermore, imaging data have revealed that gray 
matter volume loss over time is twice as fast among cocaine addicts as in healthy individu-
als. Given that gray matter volume in prefrontal cortex has been related to working memory 
performance, these findings are in keeping with the idea that long-term cocaine use may cause 
sustained deleterious effect on working memory.
3. Depressant drugs
Adolescence is the critical period for initiation of alcoholic beverage consumption. Epidemiologic 
studies reveal that alcohol use is remarkably common among teenagers, with increasing rates 
of alcohol abuse in the US including heavy episodic drinking [33]. After alcohol and tobacco, 
marijuana is the social drug most frequently consumed by this cohort. Additionally, a high per-
centage of alcohol abusers also consume marijuana [34]. Several studies have shown that both 
alcohol and marijuana tend to alter the structure and function of the brain and are associated 
with impaired decision-making, memory and impulsivity in young adults and adolescents 
(Table 1).
3.1. Ethanol
Evidence shows a direct correlation between early onset of alcohol intake and alcohol-related 
problems in adulthood, suggesting that adolescent exposure to the reinforcing properties of 
this drug increases the probability of its abuse later [35]. However, as for other addictive sub-
stances, the effect of exposure to alcohol depends to a great extent on how much and for how 
long it is consumed.
Acute alcohol intake has a biphasic effect on brain activity, causing excitation and euphoria 
at low blood concentration and depression as it increases [36]. However, regarding cognitive 
functions, experimental data have been inconsistent using a variety of cognitive tests. Thus, 
low or moderate doses of alcohol, relative to placebo, produced facilitation [37, 38], deficits 
[39] or no change [40] in memory performance at subtoxic amounts (<65 mg/dl). Moreover, it 
apparently does not produce adverse effects and may even slightly improve working memory 
in nonproblem drinkers, regardless of sex [41]. However, as the dose of alcohol increases, 
confusion, loss of awareness and selective attention begin to occur, significantly diminishing 
the execution of working memory and its long-term consolidation. The effect of alcohol on 
long-term memory formation is much greater than its impact on the capacity to remember 
previously consolidated memories or to retrieve short-term memory. It is well known that 
if subjects are asked to repeat newly acquired information following short delays (seconds) 
after its presentation while intoxicated, they often do fine [42]. Likewise, they are able to 
retrieve information acquired before acute intoxication. On the contrary, subjects perform 
very poorly using delays longer than 20 min, particularly if they are distracted between the 
stimulus presentation and testing [43].
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As studies indicate that the extent of alcohol-induced memory deficits increases with the dose 
but maintains the same pattern (i.e., greater difficulty at forming new long-term memories 
than recalling the existing ones), it appears that this drug mostly affects memory consolidation.
Unfortunately, during adolescent life, repeated intoxication with high doses of alcohol 
becomes more frequent and memory impairments are more profound, commonly resulting 
in blackouts, that is, a complete incapability to remember all or part of a drinking event [44]. 
Heavy alcohol drinking associated with blackouts [45] does not necessarily involve loss of 
consciousness, but rather a failure to transfer information from short- to long-term memory 
[46]. Individuals with a history of blackouts show episodic memory impairments while intoxi-
cated [47], particularly at retrieving the spatiotemporal context of events [48]. Moreover, long-
term (3 years) heavy alcohol intake in adolescents between 15 and 19 years of age induced 
memory deficits [49] as well as volume reduction in subcortical and temporal regions [50].
The mechanisms underlying alcohol-induced memory disruption are still elusive. Throughout 
several decades, it was supposed that alcohol produces a nonspecific general depression of 
brain activity. Later, research led to assumption that alcohol depressed the activity of neurons 
by altering the fluidity of the neuronal membrane and consequently the activity of proteins, 
including ion channels that might, in turn, produce synaptic dysfunctions [51].
It was not until recently that new pharmacological information regarding the effects of alco-
hol on neural cells revealed that this drug has actually very selective effects on various neu-
rotransmitter systems, both excitatory, e.g., glutamatergic and cholinergic, and inhibitory, 
such as GABAergic, glycinergic and serotonergic among others. Alcohol could alter the activ-
ity of specific receptor subtypes as well [52]. All these neurotransmission mechanisms have a 
deep impact on cognitive functions. Paradoxically, repeated alcohol exposure might promote 
the formation of a particular drug-reward–associated implicit memory that could underlay 
its addiction [53].
The main risk of alcohol ingestion early in life is that the adolescent brain is still in a maturation 
period and drug intoxication greatly affects its development and the individual’s future life.
3.2. Cannabis
Recently, endocannabinoids, endogenous ligands that bind to and activate the same receptors 
as 9-delta-tetrahydrocannabinol (THC), the psychoactive component of cannabis, were found to 
play an important role in the diminution of gray matter [3]. Cannabis is the third most prevalent 
drug of abuse among teenagers, behind alcohol and tobacco [54]. Many studies in humans have 
shown that chronic cannabis consumption, especially when initiated early in life, correlates 
with a range of cognitive impairments in adulthood, including learning and memory deficits. 
Meanwhile, the evidence remained equivocal, partly due to the myriad of confounding factors, 
characteristic of human studies, as well as different methodology employed by the distinct 
studies, some unveiling clear effects, while others finding marginal or no effects [55]. However, 
in recent years, a clearer picture is emerging, which seems to suggest that teenage cannabis 
consumption may indeed have long-term detrimental effects on cognitive processes, including 
memory. The present section surveys the evidence linking adolescent cannabis  consumption 
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and prevailing memory deficits. We will further discuss the present state of knowledge on such 
questions as how is it that cannabis consumption can affect memory? Is memory homogenously 
affected or are there certain types of memory more impaired? Also, if cannabis intake during 
adolescence affects brain function in the long-term, are such sequelae reversible?
First, as for the acute effects of marijuana consumption, impaired working memory during 
the acute phase of cannabis intoxication has been observed in several studies [55, 56]. For 
instance, randomized clinical trials with dronabinol, a synthetic derivate of THC, revealed 
impaired verbal fluency, working memory and executive functions in healthy subjects during 
and in the hours following intoxication [57]. On the other hand, other works on healthy sub-
jects found that performance on verbal working memory was left unaffected but that the tasks 
elicited a higher activation of parahippocampal areas, which may indicate either “neurophys-
iological inefficiency” or alternate/compensatory neural mechanisms in these subjects [58]. 
This is consistent with another fMRI study that was conducted on otherwise healthy adults 
that were current marijuana users and that showed hyperactivation during a verbal working 
memory challenge, which the authors suggest may be related to suboptimal efficiency during 
cognitive challenge in this group [59]. Finally, another study by the same group showed that 
the frequency of cannabis use is positively correlated to blood oxygenation level–dependent 
signal in the left parahippocampal gyrus during a visual associative memory task, regardless 
of the age of onset (early vs. late adolescence) [60].
But beyond the acute intoxication phase, one obvious question is whether cannabis consump-
tion produces long-term sequelae on cognition. Working memory performance appears to 
be especially sensitive to cannabis consumption in the early teenage years (before the age of 
16–17). Testing 122 long-term heavy cannabis users on a corroborated 28-day abstinence period 
and 87 control subjects, Pope and collaborators showed that although adult-onset cannabis 
users hardly differed from controls, those that started before the age of 17 were impaired in 
a series of cognitive tests, most especially in verbal memory [61]. Further research has shown 
that the observed cannabis-induced deficits may prevail even after 6 weeks of discontinuation; 
although after 3 months of complete discontinuation, no difference was observed between pre-
vious heavy users and controls [62]. However, a more recent study in adolescents 18–20 years 
old with a history of chronic, heavy cannabis use, while performance in a verbal memory test 
was comparable to that of age-matched controls, a significant bilateral atrophy was observed, 
even after 6 months of supervised drug abstinence [63]. The putative detrimental effects of can-
nabis use appear to be dose-dependent. For example, performance in the Rey Auditory Verbal 
Learning Test correlated negatively with the number of years of cannabis misuse [64].
However, these results did not allow to determine whether cannabis had long-term detrimen-
tal effects on the cognitive abilities and brain functioning of these youths once they reached 
adulthood or whether a preexisting set of slight cognitive deficiencies such as lower verbal 
memory somewhat predisposed these youths to maladaptive behaviors including early-
onset cannabis consumption. More to the point, as the authors pointed out, even if the toxic 
effects of cannabis were the culprit, it was impossible to determine in the light of these results, 
whether the observed differences were due to long-term effects of cannabis on these subjects 
or more short-term effects during adolescence that made them perform poorly at school and 
therefore made them less prone to develop these cognitive skills through adulthood.
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In this regard, a recent widely reaching analysis from the Cannabis Cohorts Research Con-
sortium using data from three distinct longitudinal studies started to shed light on this issue 
[57]. The study found that young adults that were cannabis users as teenagers were more likely 
to experience adverse outcomes as diverse as cannabis addiction, suicide attempt and high-
school dropout. Importantly, the authors report that controlling for the potential confounding 
factors present, both before and during adolescence and spanning individual, parental and 
peer factors, failed to abolish most of the associations observed. Along with the fact that they 
also observed a dose-response relation, heavy users having the poorest outcomes as adults, 
the findings support the hypothesis that teenage marijuana consumption has long-term det-
rimental effects on cognition, memory and general well-being. Finally, preclinical research 
brought further support for a causal relationship between teenage cannabis consumption and 
adult cognitive impairments; chronic consumption of cannabis in rats during adolescence, but 
not adulthood, impaired spatial working memory when tested as adults [65, 66].
4. Prescription drugs
According to the Anxiety and Depression Association of America, mental disorders are com-
mon among children in the United States. Anxiety and major depression disorders are usu-
ally diagnosed in children between 8 and 15 years of age (National Health and Nutrition 
Examination Survey). The treatment of metal disorders in children and adolescents depends 
on the impairment degree. However, these treatments usually include drugs that affect cog-
nitive functions. On the other hand, during childhood and adolescence, sports activities, 
especially at college levels, are frequently a cause of painful injuries that requires acute or 
chronic treatment of anti-inflammatory and/or analgesic drugs. All these treatments that are 
administered to school students could have an impact on cognitive functions and therefore 
on academic achievement. In this section, we will discuss the effects of nonsteroidal anti-
inflammatory, anxiolytic and antidepressant drugs (Table 2).
4.1. Nonsteroidal anti-inflammatory drugs (NSAIDs)
NSAIDs are therapeutic agents commonly used in clinical practice for their analgesic, anti-
inflammatory and antipyretic activity [67]. Although these chemical compounds are structur-
ally different, they all inhibit both isoforms of the cyclooxygenase enzyme, COX-1 and COX-2, 
an enzyme responsible for inflammation and pain, which is necessary for prostaglandins and 
prostanoid synthesis [68]. Normally, COX-2 is expressed in dendritic spines of hippocampal 
and cortex neurons and has been implicated in synaptic modification, because its expression 
increases during long-term potentiation [69]. Moreover, astrocytes express prostaglandin E2 
receptors (EP) and prostaglandin E2 (PGE2), which regulate membrane excitability, synaptic 
transmission and synaptic plasticity implicated in learning and memory processes [70]. Also, 
the administration of misoprostol, an agonist of PGE2 receptors, ameliorates the long-term 
deficits observed in Huntington disease R6/1 mice by increasing the branching in hippocam-
pal neurons and stimulating the synthesis of brain-derived neurotrophic factor (BDNF) [71]. 
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Furthermore, subchronic administration of acetylsalicylic and ascorbic acids increases expres-
sion of receptors related with cognitive function such as learning and memory, while chronic 
treatment of acetylsalicylic acid lessens the spatial memory impairment observed in an exper-
imental model of Alzheimer’s disease [72]. Several reports indicate that celecoxib, a selec-
tive COX-2 inhibitor, reduces oxidative stress in a model of hypoxia reoxygenation, reducing 
the activation of microglia and astrocytes in the neonatal rat brain and improving cognitive 
function, suggesting that celecoxib may have neuroprotective actions [73]. In addition, mul-
tiple exposures to sevoflurane, a model that mimics the neurotoxicity induced by anesthesia, 
produces an increase in proinflammatory cytokines and deterioration in cognitive function 
in young mice, effects that were attenuated by the administration of ketorolac [74]. Another 
Drug Cognitive process Effect Model Reference
Prescription drugs Spatial memory 
impairment
Acute administration: Neuroprotection
Subchronic administration: improving 
cognitive functions
Chronic administration: improve spatial 
memory impairment
Rat
Mouse
[70–75]
Cognitive and emotional 
alterations
Reestablishment of the deterioration in 
memory and spatial learning
Diminish despair and memory 
impairment
Chronic administration: increase cell 
proliferation in hippocampus
Increase of BDNF levels
Human 
Rat
[78, 81–86]
Memory and learning 
impairment
Restore cognitive impairment
Improve executive function
Increase spatial memory
Mouse [88–90]
Cognition-
enhancing drugs
Formation of memories 
and performing tasks
Enhancing cognitive performance in 
Alzheimer’s disease patients
Improve cognitive functions as: verbal 
memory, attention memory, information 
processing, executive function and 
memory mood
Human [95, 96]
Alertness and enhance 
cognition
Improves attention, memory and 
executive function in sleep-deprived 
individuals
Limited effects in nonsleep deprived
Mental performance of subjects with low 
baseline performance
Human [101–105]
Attention deficit/
hyperactivity disorder
Improve cognition processes as: working 
memory, speed of processing, verbal 
learning and memory and attention
Human
Rat
[107–109, 
111]
Table 2. Effects of the prescription and cognition-enhancing drugs in cognitive functions.
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study showed that meloxicam ameliorated the depressive-like behavior, cognitive impair-
ment and neuroinflammation in hippocampus caused by chronic unpredictable mild stress 
[75]. Then, NSAIDs indirectly could disrupt cognitive functions.
4.2. Antidepressant drugs
Major depression is a common mental disorder affecting adolescents in the United States. 
According to the National Institute of Mental Health, in 2015, an estimated of 3 million ado-
lescents aged 12–17 in the United States had, at least, one major depressive episode. Major 
depressive disorder is a long-term disabling condition occurring with relapse and recur-
rences, which could become a chronic condition [76]. Among all the symptoms presented 
in this psychopathology, memory and attention deficits are considered an important clini-
cal manifestation of major depressive disorder [77]. Furthermore, cognitive and emotional 
alterations observed in depressive patients have been associated with changes in neuronal 
activity of prefrontal cortex, cingulate cortex and hippocampus. In major depressive dis-
order, orbitofrontal, ventromedial and prefrontal cortices are hypoactive, and postmortem 
evidence indicates histopathological changes in orbitofrontal and prefrontal cortex [78]. 
Additionally, significant hyperactivity in anterior cingulated cortex, inferior frontal gyrus 
and occipitoparietal regions has been observed in adolescents with major depressive disorder 
[79]. Also, a reduction in the volume of the hippocampus was reported, which is related to 
the severity and the duration of the major depressive disorder [80]. All these alterations were 
shown to contribute to changes in cognitive and emotional processing in depressive patients. 
Nevertheless, antidepressant treatment contributed to reestablish mood and cognitive func-
tions. For instance, the chronic administration of deprenyl, a monoamine-oxidase-B inhibi-
tor, reestablished the deterioration in memory and spatial learning and also diminished the 
lipid peroxidation and the neuronal loss in prefrontal cortex, striatum and hippocampus [81]. 
Moreover, treatment with desipramine, a norepinephrine reuptake inhibitor, caused rees-
tablished long-term potentiation and diminished despair and memory impairment, through 
activation of CREB in the hippocampus [82]. Similar effects were observed with fluoxetine 
(serotonin reuptake inhibitor); rats receiving a chronic treatment of fluoxetine increased cell 
proliferation and BDNF in hippocampus associated to a memory and learning improvement 
[83]. These studies suggest that antidepressants revert memory and learning deterioration 
observed in animal models of depression.
Regarding clinical studies, patients with major depressive disorder showed lower levels of 
BDNF in plasma, which correlates with memory function deficits; hence, BDNF levels increased 
after the antidepressant treatment [84]. Nevertheless, the impairment in psychomotor and 
memory processes observed in depressed treated patients has no significance for clinical pur-
poses [85]. Moreover, some evidence has shown that conventional antidepressant treatment 
selectively diminishes cognitive dysfunction [86].
The involvement of antidepressant drugs in cognitive functions is not clear; however, animal 
model studies have shown that synaptic plasticity is increased in neuronal regions involved 
in mood and memory processing [81–84].
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4.3. Anxiolytics
Cognitive impairments have been consistently reported in anxiety disorders. Benzodiazepine, 
which acts in a specific site of the GABA A receptor, has been, for many years, the first-line 
therapy for the treatment of anxiety disorders. Although benzodiazepines are attractive for their 
rapid therapeutic effect, these drugs have undesirable side effects both in the short term (e.g., 
sedation) and in the long-term (e.g., dependence and memory impairment [87]). Some reports 
have indicated that GABAergic neurotransmission in the hippocampus is involved in the mod-
ulation of learning and memory functions [88]. Also, the administration of an inverse agonist of 
α5 subtype GABA A receptors (RO4938581) enhances long-term potentiation in hippocampus, 
restores the cognitive impairment caused by the scopolamine treatment and improves the exec-
utive function in monkeys without affecting emotional state [89]. Furthermore, a partial inverse 
agonist of α5 subtype GABA A receptors increased spatial memory [90]. These studies indicate 
that GABAergic neurotransmission regulates memory and learning processes, which opens the 
possibility of designing new selective molecules with clinical utility, not just for treating anxiety 
disorders, but also for improving cognitive functions.
5. Cognition-enhancing drugs
The search for drugs that improve cognitive functions to treat several diseases, including 
Alzheimer disease (AD), attention deficit disorder (ADD), attention deficit hyperactivity dis-
order (ADHD), has derived a wide number of synthetic drugs that, in turn, increase learning, 
executive functions, or creativity in healthy people. These drugs, also named “smart drugs” or 
“nootropics,” have different chemical origins and mechanisms and in general have showed little 
or no effect in improving learning and memory tasks. There is a growth in the consumption of 
these drugs by adolescents [91, 92], mainly due to academic demands and competitiveness [93]. 
According to the Federal Substance Abuse and Mental Health Services Administration, every 
year around 137,000 college students in the US begin to use psychostimulants. Furthermore, 
consumption of stimulant drugs of abuse increases in key academic dates (Table 2) [94].
Nootropics have focused their targets on modulation of neurotransmission, hormones, trans-
duction systems and neuron metabolism. However, we will focus on legal stimulants com-
monly used by students to improve academic performance: acetylcholinesterase inhibitors, 
memantine, modafinil and methylphenidate.
5.1. Antidementia drugs
5.1.1. Acetylcholinesterase inhibitors (AChEIs)
Most of the drugs that are used to enhance cognitive functions, both in patients and in healthy 
volunteers, work through acetylcholine (ACh) neurotransmission. ACh is a neurotransmitter 
closely involved in synaptic transmission and also in the formation of memories and per-
forming tasks. Donepezil, rivastigmine or galantamine had good results enhancing  cognitive 
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 performance in patients with mild to moderate AD, when compared with placebo [95]. 
However, diverse studies conducted in healthy volunteers have showed that AChEIs lightly 
improve verbal memory after semantic processing of words, attention memory, information 
processing, executive function and memory mood [96].
5.1.2. Memantine
Memantine is a psychostimulant used to treat moderate to severe AD. It acts on the glu-
tamatergic system by antagonizing N-methyl-d-aspartate (NMDA) receptors. This drug has 
been showed to slightly improve cognitive functions as monotherapy of AD [97]. There are 
few studies about the cognitive-enhancing capacity of memantine on healthy volunteers. The 
studies published were tested with acute single dose of memantine, finding that this drug 
does not increase mental performance significantly [96].
5.2. Modafinil
Modafinil is a psychostimulant indicated in the treatment of narcolepsy, shift work sleep dis-
order and excessive daytime sleepiness [98]. Since approval by FDA, in 1998, modafinil has 
been widely used not only to treat wakefulness disorders, but also to increase alertness and 
enhance cognition. Modafinil exhibits advantages among other psychostimulants, including 
the lack of unwanted side effects (e.g., tolerance, abuse potential, sleep rebound and locomo-
tor excitability) [99], and, in most countries, it is not a controlled substance; therefore, it can 
be easily purchased online. Modafinil exerts its actions through an unknown mechanism. 
Still, it is recognized that modafinil inhibits dopamine and noradrenaline uptake, elevates cat-
echolamine’s levels, therefore raises extracellular serotonin, glutamate, histamine and orexin 
and reduces GABA’s concentration [100]. Although the effects of modafinil as a wakefulness 
promoter have been proven [101], its properties as cognitive enhancer are still controversial. 
In sleep-deprived individuals, modafinil improves attention, memory and executive func-
tion [102], while the effects of modafinil in non–sleep-deprived adolescents are limited [103]. 
Other reports have found that modafinil actually improves several cognitive functions [104]. 
Interestingly, modafinil has showed to enhance mental performance of subjects with low 
baseline performance or IQ on several tasks evaluated [105].
5.3. Methylphenidate (MPH)
MPH (Ritalin©) is a psychostimulant approved for the treatment of attention deficit/hyperac-
tivity disorder (ADD/ADHD) [106]. Additionally, MPH is one of the most effective cognitive 
enhancers used by healthy people [107], because it acts through a mechanism analogous to 
that of cocaine: increases the levels of the catecholamines, dopamine, norepinephrine and 
serotonin, by blocking their transport [108]. This drug improves working memory, speed of 
processing, verbal learning and memory and attention [102]. Nevertheless, MPH effects are 
not restricted to spatial problems, since it also improves digit span test score [109]. Although 
MPH has demonstrated to be effective and safe in most of the patients when used in the short 
term, several side effects have been reported: decrease of appetite, insomnia, headache, irri-
tability, weight loss, sadness, abdominal pain, nausea, somnolence, dizziness, among  others. 
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Several studies have reported that MPH treatment during childhood produces “permanent” 
changes in behavioral responses to other psychostimulants [110]. Moreover, a recent study 
made on rats has showed that acute and long-term exposure of adolescents to MHP has 
important effects on reward-dependent learning and decision [111].
5.4. Considerations about use and misuse of cognition-enhancing drugs
There are some difficulties evaluating the efficacy of smart drugs, mainly due to the heteroge-
neity of subjects and the differences in the cognitive evaluation methods. Besides, the dispari-
ties in the design of the studies have been challenging the evaluation of smart drugs in healthy 
subjects. However, there are some studies that have used systematic methodology to analyze 
the literature published on healthy volunteers [96, 97]. According to these reviews, antide-
mentia drugs, AChEIs and memantine enhance cognitive functions in patients with AD; nev-
ertheless, their effects on healthy volunteers appear to be very poor [107]. Another aspect 
to consider is the interindividual variability of volunteers, because it could be an important 
reason that masks the cognitive effect of these drugs.
There are also several ethical considerations about the use of psychostimulants in healthy 
people. Currently, caffeine is the stimulant most commonly used to get alertness. However, 
the misuse of MPH and modafinil is growing among students, since these drugs are cheap and 
easy to obtain illegally.
6. Perspectives
Drug abuse and addiction to legal and illegal substances have become a major challenge in 
western developed and developing societies. Growing evidence has shown that the onset 
age of drug consumption is around 15 years. At this age, the central nervous system is still 
under maturation. Childhood and adolescence are critical stages for neural and social devel-
opment. Therefore, worldwide increasing prevalence of drug abuse among teenagers will 
certainly have an effect on scholar performance. All the evidence described in the present 
review suggests that teenagers that consume drugs risk deleterious consequences in their 
academic growth, since the neural mechanisms targeted by these drugs may have long-term 
impacts on cognitive functions. Therefore, prevention initiatives and public health programs 
must be implemented in schools to protect children and teenagers from escalating drug use.
7. Conclusion
In summary, the evidence regarding the possible long-term detrimental effects of teenage 
drug consumption on learning and memory adds to the increased risk of developing mental 
disorders, and therefore it should be included in public health information campaigns that 
seek to encourage delaying and/or reducing drug consumption at this stage of life. The sci-
entific information obtained from studies such as those described above will be of little use 
without adequate public policies aimed at alleviating this serious problem.
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